An international team of scientists compared the effectiveness of different chemicals and monoclonal antibodies in naturalizing the Omicron BA 4.6 subvariant. Subvariant BA 4.6. is currently the second dominant Omicron subvariant after BA. 5. It turned out that antiviral chemicals such as remdesivir, molnupiravir and nirmatrelvir as well as monoclonal antibodies bebtelovimab and imdevimab retain their effectiveness in neutralizing BA.4.6 in vitro. On the other hand, monoclonal antibodies such as casirivimab, sotrovimab, tixagevimab and cilgavimab are not very effective against BA.4.6. The paper was published in NEJM.